From a Gene Mutation to Pathology and Targeted Therapy in a Patient with Therapy-resistant Porokeratosis

Kostopoulos-Kanitakis KA, Kanitakis J. Porokeratoses: an update on pathogenesis and treatment. Int J Dermatol 2025; 64: 62–71. DOI: https://doi.org/10.1111/ijd.17411

Atzmony L, Choate KA. Second-hit somatic mutations in mevalonate pathway genes underlie porokeratosis. J Invest Dermatol 2019; 139: 2409–2411. DOI: https://doi.org/10.1016/j.jid.2019.07.723

Byth LA, Byth J. Topical simvastatin-cholesterol for disseminated superficial actinic porokeratosis: an open-label, split-body clinical trial. Australas J Dermatol 2021; 62: 310–313. DOI: https://doi.org/10.1111/ajd.13601

van der Burgh R, Ter Haar NM, Boes ML, Frenkel J. Mevalonate kinase deficiency, a metabolic autoinflammatory disease. Clin Immunol 2013; 147: 197–206. DOI: https://doi.org/10.1016/j.clim.2012.09.011

Santa Lucia G, Snyder A, Lateef A, Drohan A, Gregoski MJ, Barton V, et al. Safety and efficacy of topical lovastatin plus cholesterol cream vs topical covastatin cream alone for the treatment of disseminated superficial actinic porokeratosis: a randomized clinical trial. JAMA Dermatol 2023; 159: 488–495. DOI: https://doi.org/10.1001/jamadermatol.2023.0205

Bekkering S, Arts RJW, Novakovic B, Kourtzelis I, van der Heijden CDCC, Li Y, et al. Metabolic induction of trained immunity through the mevalonate pathway. Cell 2018; 172: 135–146. DOI: https://doi.org/10.1016/j.cell.2017.11.025

Tan LS, Chong WS. Porokeratosis in Singapore: an Asian perspective. Australas J Dermatol 2012; 53: e40–44. DOI: https://doi.org/10.1111/j.1440-0960.2011.00856.x

Zhu PQ, Yan HM, Zhao HJ, Guo DY, Jiang W. A novel premature termination mutation in FDPS in a Chinese family with disseminated superficial actinic porokeratosis. Br J Dermatol 2019; 180: 1545–1546. DOI: https://doi.org/10.1111/bjd.17531

Li L, Zuo N, Yang D, Zhang D, Feng Y, Li X. Novel missense mutations of MVK and FDPS gene in Chinese patients with disseminated superficial actinic porokeratosis. Clin Chim Acta 2021; 523: 441–445. DOI: https://doi.org/10.1016/j.cca.2021.10.026

Wang X, Ouyang X, Zhang D, Zhu Y, Wu L, Xiao Z, et al. Two novel and three recurrent mutations in the mevalonate pathway genes in Chinese patients with porokeratosis. Clin Cosmet Investig Dermatol 2024; 17: 191–197. DOI: https://doi.org/10.2147/CCID.S444985

Li M, Li Z, Wang J, Ni C, Sun Z, Wilson NJ, et al. Mutations in the mevalonate pathway genes in Chinese patients with porokeratosis. J Eur Acad Dermatol Venereol 2016; 30: 1512–1517. DOI: https://doi.org/10.1111/jdv.13653

Shi W, Fu X, Wang Z, Mi Z, Zhang H, Yu G, et al. Twenty-two novel mutations in a Chinese cohort of 137 patients with porokeratosis were identified using microfluidics (Fluidigm). J Dermatol Sci 2021; 101: 75–77. DOI: https://doi.org/10.1016/j.jdermsci.2020.10.013

Pontillo A, Paoluzzi E, Crovella S. The inhibition of mevalonate pathway induces upregulation of NALP3 expression: new insight in the pathogenesis of mevalonate kinase deficiency. Eur J Hum Genet 2010; 18: 844–847. DOI: https://doi.org/10.1038/ejhg.2010.9

Atzmony L, Lim YH, Hamilton C, Leventhal JS, Wagner A, Paller AS, et al. Topical cholesterol/lovastatin for the treatment of porokeratosis: a pathogenesis-directed therapy. J Am Acad Dermatol 2020; 82: 123–131. DOI: https://doi.org/10.1016/j.jaad.2019.08.043

Ugwu N, Choate KA, Atzmony L. Two percent lovastatin ointment as a pathogenesis-directed monotherapy for porokeratosis. JAAD Case Rep 2020; 6: 1110–1112. DOI: https://doi.org/10.1016/j.jdcr.2020.08.017